Background: Recurrent asthma-like symptoms are common in infants, but few population studies describe diagnostic and treatment practice.
Methods: Using the electronic data repository of Clalit Health Services, the largest integrated health care provider in Israel, we evaluated children born 2005-2012, who before 3 years of age had >3 episodes of asthma-like symptoms and/or >2 bronchodilator purchases within a year. We described health care utilization and the odds ratio for subsequent utilization after 3 and 12 months' controller therapy. The primary outcome measure was respiratory-related doctor visits. Linear and categorical regression analysis measured overall effectiveness of therapy.
Results: Among 689 171 infants, 262 900 (38.1%) had > 3 asthma-like episodes/year during at least 1 year. Of those, 26 108 (10%) purchased controller therapy: 20 316 (77.8%) inhaled corticosteroids (ICS) with or without leukotriene receptor antagonists (LTRA), and 5792 (22.2%) LTRA alone. For these 26 108 over 3 months there were 93 845 respiratory-related doctor visits, 3110 hospital admissions, 5568 diagnoses of pneumonia, 9960 chest X-rays, 37 127 purchases for oral steroids, and 45 142 for antibiotics courses. Healthcare utilization decreased following ICS ± LTRA and LTRA alone, respectively, as follows: doctor visits 7% and 3%, chest X-rays 16% and 17%, bronchodilators 20% and 11%, systemic steroids 17% and 12%, and antibiotics by 35% and 22%, (P < .001 for all). Twelve months' therapy remained effective.
Conclusions: Asthma-like symptoms are common in infants. Health care utilization is very high and physician practices should be reassessed. Following controller therapy, health care utilization decreased. Yet controllers were prescribed in only a minority of eligible children.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ppul.24429 | DOI Listing |
Lung
January 2025
Department of Pathology, The Second People's Hospital of China Three Gorges University/ Yichang Second People's Hospital, Yichang, 443000, Hubei, China.
Background: Some studies have suggested that the forced expiratory flow between 25 and 75% of vital capacity (FEF) can be used as an early marker of bronchial hyperresponsiveness (BHR) in asthma and allergic rhinitis (AR), but is highly variable. Here, we aimed to assess whether the FEF can be used to diagnose BHR in patients with asthma-like symptoms and AR.
Methods: PubMed, EMBASE, Web of Science, Wiley Online Library, Cochrane Library, SinoMed, CNKI, and Wanfang Data were searched to acquire eligible studies.
Front Pharmacol
November 2024
Experimental Asthma and Allergy Research Unit, Institute of Environmental Medicine (IMM), Karolinska Institutet, Stockholm, Sweden.
Background: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are important causes of morbidity and mortality in critically ill patients. Gastric contents aspiration is one of the most common causes of ALI/ARDS. To date, there are still no specific and effective pharmacological treatments for ALI/ARDS.
View Article and Find Full Text PDFInflammatory myofibroblastic tumour is a rare tumour. We present an atypical case of Inflammatory myofibroblastic tumour which was trachea in location, histocyte rich and ROS1 rearranged. The patient presented with upper airway obstruction, which was an asthma mimic.
View Article and Find Full Text PDFPediatrics
December 2024
Philadelphia, Pennsylvania.
Introduction: Asthma is a common respiratory condition; however, its symptoms often overlap with other diseases, posing diagnostic challenges. Tracheal stenosis, often seen in patients with a history of intubation, can mimic asthma symptoms, leading to misdiagnosis.
Case Study: This case study discusses a 58-year-old female with hypertension, type 2 diabetes, and obesity.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!